{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:20:57Z","timestamp":1777382457177,"version":"3.51.4"},"reference-count":75,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2004,8,1]],"date-time":"2004-08-01T00:00:00Z","timestamp":1091318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2004,8]]},"DOI":"10.1016\/j.cld.2004.04.011","type":"journal-article","created":{"date-parts":[[2005,4,18]],"date-time":"2005-04-18T17:29:14Z","timestamp":1113845354000},"page":"715-728","source":"Crossref","is-referenced-by-count":12,"title":["Pharmacologic management of nonalcoholic fatty liver disease"],"prefix":"10.1016","volume":"8","author":[{"given":"Stephen A.","family":"Harrison","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brent A.","family":"Neuschwander-Tetri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cld.2004.04.011_BIB1","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0002-9343(99)00271-5","article-title":"Association of nonalcoholic fatty liver disease with insulin resistance","volume":"107","author":"Marchesini","year":"1999","journal-title":"Am J Med"},{"key":"10.1016\/j.cld.2004.04.011_BIB2","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1053\/gast.2001.23256","article-title":"Nonalcohlic steatohepatitis: association of insulin resistance and mitochondrial abnormalities","volume":"120","author":"Sanyal","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2004.04.011_BIB3","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/35007508","article-title":"Obesity as a medical problem","volume":"404","author":"Kopelman","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.cld.2004.04.011_BIB4","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.2337\/diacare.24.11.1936","article-title":"Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the US","volume":"24","author":"Boyle","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cld.2004.04.011_BIB5","first-page":"3","article-title":"Fat and the liver\u2014a molecular overview","volume":"13","author":"Harrison","year":"2002","journal-title":"Semin Gastrointest Dis"},{"key":"10.1016\/j.cld.2004.04.011_BIB6","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/0046-8177(89)90249-9","article-title":"Nonalcoholic steatohepatitis: a study of 39 patients","volume":"20","author":"Lee","year":"1989","journal-title":"Hum Pathol"},{"key":"10.1016\/j.cld.2004.04.011_BIB7","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/hep.1840110114","article-title":"The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years","volume":"11","author":"Powell","year":"1990","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2004.04.011_BIB8","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/0016-5085(94)90235-6","article-title":"Nonalcoholic steatohepatitis: an expanded clinical entity","volume":"107","author":"Bacon","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2004.04.011_BIB9","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1111\/j.1572-0241.2001.04667.x","article-title":"Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease","volume":"96","author":"Willner","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2004.04.011_BIB10","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/gast.2002.34168","article-title":"Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma","volume":"123","author":"Bugianesi","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2004.04.011_BIB11","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1053\/gast.2002.34453","article-title":"Is hepatocellular carcinoma part of the natural history of nonalcoholic steatohepatitis?","volume":"123","author":"Ong","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2004.04.011_BIB12","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0025-6196(24)00530-5","article-title":"Nonalcoholic steatohepatitis: Mayo Clinic experience with a hitherto unnamed disease","volume":"55","author":"Ludwig","year":"1980","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.cld.2004.04.011_BIB13","first-page":"412A","article-title":"Clinical factors associated with fibrosis in 102 patients with nonalcoholic steatohepatitis","volume":"36","author":"Harrison","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2004.04.011_BIB14","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1002\/hep.510300604","article-title":"Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis","volume":"30","author":"Angulo","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2004.04.011_BIB15","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1053\/jhep.2002.33892","article-title":"HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity","volume":"36","author":"Chitturi","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2004.04.011_BIB16","first-page":"18","article-title":"The relationship of obesity to the metabolic syndrome","volume":"134","author":"Lebovitz","year":"2003","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.cld.2004.04.011_BIB17","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1053\/jhep.2003.50161","article-title":"Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome","volume":"37","author":"Marchesini","year":"2003","journal-title":"Hepatology"},{"issue":"6 Suppl","key":"10.1016\/j.cld.2004.04.011_BIB18","doi-asserted-by":"crossref","first-page":"S438","DOI":"10.1097\/00005768-200106001-00012","article-title":"The acute versus the chronic response to exercise","volume":"33","author":"Thompson","year":"2001","journal-title":"Med Sci Sports Exerc"},{"key":"10.1016\/j.cld.2004.04.011_BIB19","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1053\/beem.2002.0225","article-title":"Obesity and liver disease","volume":"16","author":"Scheen","year":"2002","journal-title":"Best Prac Res Clin Endocrinol Metab"},{"key":"10.1016\/j.cld.2004.04.011_BIB20","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1172\/JCI13505","article-title":"Role of AMP-activated protein kinase in mechanism of metformin action","volume":"108","author":"Zhou","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cld.2004.04.011_BIB21","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0016-5085(98)70599-2","article-title":"Steatohepatitis: a tale of two \u201chits\u201d? [editorial]","volume":"114","author":"Day","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2004.04.011_BIB22","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1016\/0016-5085(90)91169-7","article-title":"Effect of weight reduction on hepatic abnormalities in overweight patients","volume":"99","author":"Palmer","year":"1990","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2004.04.011_BIB23","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0168-8278(97)80287-5","article-title":"Therapeutic effects of restricted diet and exercise in obese patients with fatty liver","volume":"27","author":"Ueno","year":"1997","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2004.04.011_BIB24","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/BF02233443","article-title":"Liver morphology and function tests in obesity and during total starvation","volume":"12","author":"Rozental","year":"1967","journal-title":"Am J Dig Dis"},{"key":"10.1016\/j.cld.2004.04.011_BIB25","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/0168-8278(91)90942-5","article-title":"Hepatic effects of dietary weight loss in morbidly obese patients","volume":"12","author":"Anderson","year":"1991","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2004.04.011_BIB26","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1210\/jc.84.11.4293","article-title":"Parallel reversibility of biological markers of the metabolic syndrome and liver steatosis after gastroplasty-induced weight loss in severe obesity","volume":"84","author":"Luyckx","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.cld.2004.04.011_BIB27","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1592\/phco.20.4.270.34882","article-title":"Orlistat, a new lipase inhibitor for the management of obesity","volume":"20","author":"Heck","year":"2000","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cld.2004.04.011_BIB28","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/j.1572-0241.2003.07375.x","article-title":"Orlistat in the treatment of NASH: a case series","volume":"98","author":"Harrison","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2004.04.011_BIB29","first-page":"406A","article-title":"Orlistat treatment in obese, nonalcoholic steatohepatitis patients: a pilot trial","volume":"36","author":"Harrison","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2004.04.011_BIB30","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1053\/jhep.2003.50132","article-title":"Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis","volume":"37","author":"Musso","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2004.04.011_BIB31","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/hep.510230624","article-title":"Ursodeoxycholic acid or clofibrate in the treatment of nonalcohol-induced steatohepatitis: a pilot study","volume":"23","author":"Laurin","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2004.04.011_BIB32","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S0168-8278(99)80243-8","article-title":"A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis","volume":"31","author":"Basaranoglu","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2004.04.011_BIB33","doi-asserted-by":"crossref","first-page":"A544","DOI":"10.1016\/S0016-5085(08)82704-7","article-title":"Atorvastatin for the treatment of NASH","volume":"120","author":"Horlander","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2004.04.011_BIB34","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/00004836-200303000-00015","article-title":"Probucol in the treatment of nonalcoholic steatohepatitis: an open-labeled study","volume":"36","author":"Merat","year":"2003","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.cld.2004.04.011_BIB35","doi-asserted-by":"crossref","first-page":"12953","DOI":"10.1074\/jbc.270.22.12953","article-title":"An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)","volume":"270","author":"Lehmann","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cld.2004.04.011_BIB36","doi-asserted-by":"crossref","first-page":"797","DOI":"10.2337\/diabetes.51.3.797","article-title":"The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes","volume":"51","author":"Mayerson","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.cld.2004.04.011_BIB37","doi-asserted-by":"crossref","first-page":"25226","DOI":"10.1074\/jbc.M202489200","article-title":"The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways","volume":"277","author":"Fryer","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cld.2004.04.011_BIB38","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2337\/diabetes.51.2.443","article-title":"Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110\u03b2 protein levels in skeletal muscle of type 2 diabetic subjects","volume":"51","author":"Kim","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.cld.2004.04.011_BIB39","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1053\/gast.2002.33666","article-title":"Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro","volume":"122","author":"Galli","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2004.04.011_BIB40","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1572-0241.2001.03553.x","article-title":"A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis","volume":"96","author":"Caldwell","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2004.04.011_BIB41","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1111\/j.1572-0241.2001.03809.x","article-title":"Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus","volume":"96","author":"Menon","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2004.04.011_BIB42","doi-asserted-by":"crossref","first-page":"38","DOI":"10.7326\/0003-4819-129-1-199807010-00009","article-title":"Troglitazone-induced hepatic failure leading to liver transplantation","volume":"129","author":"Neuschwander-Tetri","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cld.2004.04.011_BIB43","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1053\/S1542-3565(03)00198-8","article-title":"Effect of pioglitazone on biochemical indices of nonalcoholic fatty liver disease in upper body obesity","volume":"1","author":"Shadid","year":"2003","journal-title":"Clin Gastro Hepatol"},{"issue":"Suppl","key":"10.1016\/j.cld.2004.04.011_BIB44","doi-asserted-by":"crossref","first-page":"A546","DOI":"10.1016\/S0016-5085(08)82715-1","article-title":"The use of pioglitazone on nonalcohlic steatohepatitis [abstract]","volume":"120","author":"Acosta","year":"2001","journal-title":"Gastroenterology"},{"issue":"Suppl","key":"10.1016\/j.cld.2004.04.011_BIB45","first-page":"382A","article-title":"A randomized controlled pilot study of pioglitazone and vitamin E versus vitamin E for nonalcoholic steatohepatitis [abstract]","volume":"36","author":"Sanyal","year":"2002","journal-title":"Hepatology"},{"issue":"Suppl","key":"10.1016\/j.cld.2004.04.011_BIB46","doi-asserted-by":"crossref","first-page":"A708","DOI":"10.1016\/S0016-5085(03)83577-1","article-title":"Pilot study of pioglitazone in nonalcoholic steatohepatitis [abstract]","volume":"124","author":"Promrat","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2004.04.011_BIB47","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1053\/jhep.2003.50420","article-title":"Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-\u03b3 ligand rosiglitazone","volume":"38","author":"Neuschwander-Tetri","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2004.04.011_BIB48","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0168-8278(03)00027-8","article-title":"Interim results of a pilot study demonstrating the early effects of the PPAR-\u03b3 ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis","volume":"38","author":"Neuschwander-Tetri","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2004.04.011_BIB49","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/79697","article-title":"Metformin reverses fatty liver disease in obese, leptin-deficient mice","volume":"6","author":"Lin","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.cld.2004.04.011_BIB50","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0140-6736(01)06042-1","article-title":"Metformin in non-alcoholic steatohepatitis","volume":"358","author":"Marchesini","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.cld.2004.04.011_BIB51","first-page":"A621","article-title":"Metformin in non alcoholic steatohepatitis (NASH): efficacy and safety: a preliminary report","volume":"1222","author":"Nair","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2004.04.011_BIB52","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0016-5085(03)00695-4","article-title":"Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II","volume":"125","author":"Bataller","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2004.04.011_BIB53","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1159\/000069792","article-title":"Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor","volume":"23","author":"Yoshiji","year":"2002","journal-title":"Tumour Biol"},{"key":"10.1016\/j.cld.2004.04.011_BIB54","first-page":"583","article-title":"The expression of AT1 receptor on hepatic stellate cells in rat fibrosis induced by CCl4","volume":"114","author":"Wei","year":"2001","journal-title":"Chinese Med J"},{"key":"10.1016\/j.cld.2004.04.011_BIB55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-200363220-00001","article-title":"Advances in the understanding and treatment of nonalcoholic fatty liver disease","volume":"63","author":"Harrison","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.cld.2004.04.011_BIB56","first-page":"361A","article-title":"Vitamin E but not glutathione precursors inhibits hepatic fibrosis in experimental NASH exhibiting oxidative stress and mitochondrial abnormalities","volume":"34","author":"Phung","year":"2001","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2004.04.011_BIB57","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/hep.1840160426","article-title":"Vitamin E dietary supplementation protects against carbon tetrachloride-induced chronic liver damage and cirrhosis","volume":"16","author":"Parola","year":"1992","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2004.04.011_BIB58","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0014-5793(92)81290-3","article-title":"Vitamin E dietary supplementation inhibits tissue growth factor beta-1 gene expression in the rat liver","volume":"308","author":"Parola","year":"1992","journal-title":"FEBS Lett"},{"key":"10.1016\/j.cld.2004.04.011_BIB59","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1067\/mpd.2000.106566","article-title":"Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study","volume":"136","author":"Lavine","year":"2000","journal-title":"J Pediatr"},{"key":"10.1016\/j.cld.2004.04.011_BIB60","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1046\/j.1365-2036.2001.01083.x","article-title":"Plasma transforming growth factor-1 level and efficacy of \u03b1-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study","volume":"15","author":"Hasegawa","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2004.04.011_BIB61","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1111\/j.1572-0241.2003.08699.x","article-title":"Vitamin E and vitamin C in the treatment of nonalcoholic steatohepatitis","volume":"98","author":"Harrison","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2004.04.011_BIB62","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1357-2725(99)00139-9","article-title":"S-adenosylmethionine","volume":"32","author":"Lu","year":"2000","journal-title":"Int J Biochem Cell Bio"},{"key":"10.1016\/j.cld.2004.04.011_BIB63","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0168-8278(99)80263-3","article-title":"Spanish collaborative group for the study of alcoholic liver cirrhosis. S-adenosylmethionine in the treatment of alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind multicenter clinical trial","volume":"30","author":"Mato","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2004.04.011_BIB64","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1111\/j.1572-0241.2001.04129.x","article-title":"Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study","volume":"96","author":"Abdelmalek","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2004.04.011_BIB65","first-page":"722","article-title":"Eficacy and safety of oral betaine glucuronate in nonalcoholic steatohepatitis","volume":"50","author":"Miglio","year":"2000","journal-title":"Arzneim-Forsch.\/Drug Res"},{"issue":"Suppl","key":"10.1016\/j.cld.2004.04.011_BIB66","first-page":"1498A","article-title":"Phlebotomy reduces transaminase levels in patients with chronic non-viral non-alcoholic steatohepatitis","volume":"24","author":"Desai","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2004.04.011_BIB67","doi-asserted-by":"crossref","first-page":"A1071","DOI":"10.1016\/S0016-5085(00)86044-8","article-title":"Phlebotomy reduces transaminase levels in patients with non-alcoholic steatohepatitis [abstract]","volume":"118","author":"Desai","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2004.04.011_BIB68","doi-asserted-by":"crossref","first-page":"A6679","DOI":"10.1016\/S0016-5085(00)81800-4","article-title":"Effect of phlebotomy on non-alcoholic steatohepatitis (NASH) [abstract]","volume":"118","author":"Nitecki","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2004.04.011_BIB69","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1053\/gast.2002.32403","article-title":"Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease","volume":"122","author":"Facchini","year":"2002","journal-title":"Gastroenterology"},{"issue":"Suppl","key":"10.1016\/j.cld.2004.04.011_BIB70","first-page":"A6550","article-title":"Treatment of non-alcoholic steatohepatitis with N-acetylcysteine","volume":"118","author":"Gulbahar","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2004.04.011_BIB71","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1055\/s-2001-12931","article-title":"Treatment of nonalcoholic fatty liver: present and emerging therapies","volume":"21","author":"Angulo","year":"2001","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.cld.2004.04.011_BIB72","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/hep.510230624","article-title":"Ursodeoxycholic acid or clofibrate in the treatment of nonalcohol-induced steatohepatitis: a pilot study","volume":"23","author":"Laurin","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2004.04.011_BIB73","first-page":"386A","article-title":"Effect of ursodeoxycholic acid plus diet in patients with non-alcoholic steatohepatitis","volume":"28","author":"Ceriani","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2004.04.011_BIB74","first-page":"387A","article-title":"Ursodeoxycholic acid in the treatment of nonalcoholic steatohepatitis:results of a prospective clinical controlled trial","volume":"26","author":"Guma","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2004.04.011_BIB75","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/hep.20092","article-title":"Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis:results of a randomized, placebo-controlled trial","volume":"39","author":"Lindor","year":"2004","journal-title":"Hepatology"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326104000418?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326104000418?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T19:17:45Z","timestamp":1735672665000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326104000418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8]]},"references-count":75,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,8]]}},"alternative-id":["S1089326104000418"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2004.04.011","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2004,8]]}}}